Tepotinib hydrochloride


Entry
D11073                      Drug                                   
Name
Tepotinib hydrochloride (USAN);
Tepotinib hydrochloride hydrate (JAN);
Tepmetko (TN)
Product
TEPMETKO (EMD Serono)
Formula
C29H28N6O2. HCl. H2O
Exact mass
546.2146
Mol weight
547.0478
Structure
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
Metabolizing enzyme substrate
 DG02918  CYP2C8 substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Remark
Therapeutic category: 4291
ATC code: L01EX21
Chemical structure group: DG03087
Product (DG03087): D11073<JP/US>
Efficacy
Antineoplastic, Receptor tyrosine kinase inhibitor
  Disease
Non-small cell lung cancer (MET exon 14 skipping) [DS:H00014]
Target
MET* [HSA_VAR:4233v4] [HSA:4233] [KO:K05099]
  Network
N10024  Tyrosine kinase inhibitor to MET exon 14 skipping
  Pathway
hsa04014  Ras signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa05200  Pathways in cancer
hsa05202  Transcriptional misregulation in cancer
hsa05223  Non-small cell lung cancer
Metabolism
Enzyme: CYP3A4 [HSA:1576], CYP2C8 [HSA:1558]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01E PROTEIN KINASE INHIBITORS
    L01EX Other protein kinase inhibitors
     L01EX21 Tepotinib
      D11073  Tepotinib hydrochloride (USAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Molecular Target Inhibitors
   Tepotinib
    D11073  Tepotinib hydrochloride (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D11073  Tepotinib hydrochloride (USAN); Tepotinib hydrochloride hydrate (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03087  Tepotinib
     D11073  Tepotinib hydrochloride
 Metabolizing enzyme substrate
  DG02918  CYP2C8 substrate
   DG03087  Tepotinib
    D11073  Tepotinib hydrochloride
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG03087  Tepotinib
     D11073  Tepotinib hydrochloride
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   MET family
    MET* [HSA_VAR:4233v4]
     D11073  Tepotinib hydrochloride (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11073
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11073
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11073
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D11073
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D11073
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03087  Tepotinib
 Metabolizing enzyme substrate
  DG02918  CYP2C8 substrate
   DG03087  Tepotinib
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG03087  Tepotinib
Other DBs
PubChem: 375581020
KCF data

ATOM        39
            1   N1y N    28.7700  -12.1800
            2   C1x C    28.7700  -13.5800
            3   C1x C    27.5800  -14.2800
            4   C1y C    26.3200  -13.5800
            5   C1x C    26.3200  -12.1800
            6   C1x C    27.5800  -11.4800
            7   C1a C    29.9600  -11.4800
            8   C1b C    25.1300  -14.2800
            9   O2a O    23.9400  -13.5800
            10  C8y C    22.7500  -14.2800
            11  C8x C    22.7500  -15.6800
            12  N5x N    21.4900  -16.3800
            13  C8y C    20.3000  -15.6800
            14  N5x N    20.3000  -14.2800
            15  C8x C    21.4900  -13.5800
            16  C8y C    19.1100  -16.3800
            17  C8x C    19.1100  -17.7800
            18  C8x C    17.8500  -18.4800
            19  C8x C    16.6600  -17.7800
            20  C8y C    16.6600  -16.3800
            21  C8x C    17.8500  -15.6800
            22  C1b C    15.4700  -15.6800
            23  N4y N    14.2800  -16.3800
            24  C8y C    14.2800  -17.7800
            25  C8x C    13.0200  -18.4800
            26  C8x C    11.8300  -17.7800
            27  C8y C    11.8300  -16.3800
            28  N5x N    13.0200  -15.6800
            29  O5x O    15.4700  -18.4800
            30  C8y C    10.6400  -15.6800
            31  C8x C     9.4500  -16.3800
            32  C8y C     8.1900  -15.6800
            33  C8x C     8.1900  -14.2800
            34  C8x C     9.3800  -13.5800
            35  C8x C    10.6400  -14.2800
            36  C3b C     7.0000  -16.3800
            37  N3a N     5.7400  -17.0800
            38  X   Cl   23.7300  -18.9700
            39  O0  O    27.2300  -18.9700
BOND        41
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 1
            7     1   7 1
            8     4   8 1
            9     8   9 1
            10    9  10 1
            11   10  11 2
            12   11  12 1
            13   12  13 2
            14   13  14 1
            15   14  15 2
            16   10  15 1
            17   13  16 1
            18   16  17 2
            19   17  18 1
            20   18  19 2
            21   19  20 1
            22   20  21 2
            23   16  21 1
            24   20  22 1
            25   22  23 1
            26   23  24 1
            27   24  25 1
            28   25  26 2
            29   26  27 1
            30   27  28 2
            31   23  28 1
            32   24  29 2
            33   27  30 1
            34   30  31 2
            35   31  32 1
            36   32  33 2
            37   33  34 1
            38   34  35 2
            39   30  35 1
            40   32  36 1
            41   36  37 3